Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Cost keeps many diabetics from taking needed insulin

The cost of insulin prevents many people with diabetes from taking it as directed, a small survey suggests.

Read More »

AstraZeneca’s Farxiga curbs heart failure, kidney risks

The largest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca’s Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients.

Read More »

Lilly’s Trulicity reduces heart risks in clinical study

Eli Lilly.’s top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes in a large clinical trial.

Read More »

Lilly’s two-in-one diabetes product data impresses

Eli Lilly’s new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending the company’s shares to a record high and weighing on those of arch-rival Novo Nordisk.

Read More »

Eli Lilly’s diabetes treatment meets main goal in two late-stage studies

Eli Lilly and Co.’s experimental diabetes treatment Ultra Rapid Lispro was shown to be as effective as the drugmaker’s blockbuster Humalog medicine in two late-stage studies.

Read More »

One Drop’s Apple Watch App Points to Trend in Wearable Health Devices

Personalized medicine continues to grow in importance, and having the ability to monitor health data has proven to be a significant desire for people as the number of wearable devices continues to grow.

Read More »

Roche to acquire immuno-oncology company Tusk Therapeutics

Switzerland’s Roche is buying UK-based Tusk Therapeutics in a deal that could hit EUR 655 million.

Read More »

Adults need a regular bedtime, too

Adults who have a regular bedtime are likely to weigh less than those who do not, to have lower blood sugar and to face a lower risk of heart disease and diabetes, according to a U.S. study.

Read More »

Lilly Licenses Chugai Pharma’s Oral Diabetes Drug for $50 Million Upfront

Eli Lilly signed a licensing deal for Chugai Pharmaceutical’s oral non-peptidic GLP-1 receptor agonist OWL833.

Read More »

AstraZeneca’s Diabetes Drug Farxiga Decreases Risk of Cardiovascular Disease

AstraZeneca announced positive results from the company’s Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom